Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. (15th May 2021)

• Record Type: Journal Article
• Authors: Jojima, Teruo; Sakurai, Shintaro; Wakamatsu, Sho; Iijima, Toshie; Saito, Masahiro; Tomaru, Takuya; Kogai, Takahiko; Usui, Isao; Aso, Yoshimasa
• Is Part Of: International journal of cardiology. Volume 331(2021)
• Page Start: 243
• Page End: 248
• Publication Date: 2021-05-15
• Subjects: Campesterol -- Lathosterol -- Cholesterol absorption -- Cholesterol synthesis -- Empagliflozin -- High-density lipoprotein; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2021.01.063
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background and aims: Sodium/glucose cotransporter 2 (SGLT2) inhibitors decrease plasma triglyceride levels and slightly increase low-density lipoprotein (LDL-c) and high-density lipoprotein cholesterol (HDL-c). However, the mechanisms underlying such changes in the blood lipid profile remain to be determined. We investigated how empagliflozin affects plasma markers of cholesterol absorption and synthesis, and evaluated the relationship between changes in these markers and blood lipids in patients with type 2 diabetes. Methods and results: In a randomized, active-controlled, open-label trial, 51 patients were randomly allocated in 2:1 ratio to receive empagliflozin 10 mg/day ( n = 32) or standard therapy ( n = 19) for 12 weeks. We measured plasma levels of lathosterol as a marker of cholesterol synthesis, and campesterol and sitosterol as markers of cholesterol absorption, at baseline and 12 weeks after treatment. In the empagliflozin group, serum HDL-c, but not LDL-c, significantly increased between baseline and 12 weeks (54.4 ± 16.3 vs. 58.8 ± 19.6 mg/dl; p = 0.0006), whereas in the standard therapy group, HDL-c and LDL-c remained unchanged. In the empagliflozin group, plasma campesterol also increased significantly (4.14 ± 1.88 vs. 4.90 ± 2.26 μg/ml, p = 0.0008), whereas no change in plasma campesterol or sitosterol was found in the control group. Although plasma lathosterol showed no change in the whole empagliflozin group, it decreased significantly in patients who were not taking statins. In statin non-users, plasma lathosterol decreased significantly after treatment with empagliflozin (2.71 ± 0.99 vs. 1.91 ± 0.99 μg/ml, p < 0.05). In the empagliflozin group, changes in plasma campesterol correlated positively with changes in HDL-c. Conclusion: Empagliflozin increases serum campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes. This increase may be associated with SGLT2 inhibitor-induced increases in HDL cholesterol. Highlights: Empagliflozin increases significantly plasma levels of campesterol and serum HDL cholesterol in patients with type 2 diabetes. In the empagliflozin group, changes in plasma campesterol correlated positively with changes in HDL cholesterol. Empagliflozin decreases plasma levels of lathosterol, a marker of cholesterol synthesis, only in patients with no use of statins.